Thibault Boutherin
Stock Analyst at Morgan Stanley
(3.21)
# 2,524
Out of 4,983 analysts
144
Total ratings
50.7%
Success rate
4.8%
Average return
Main Sectors:
Stocks Rated by Thibault Boutherin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgraded: Sell | $40 | $43.19 | -7.39% | 6 | Sep 11, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Buy | CHF 135.00 | CHF 116.02 | +16.36% | 14 | Sep 1, 2026 | |
| SWX: GALD Galderma Group AG | Reiterated: Hold | CHF 155.00 → CHF 160.00 | CHF 157.85 | +1.36% | 9 | Apr 27, 2026 | |
| NVS Novartis AG | Reiterated: Buy | $143 → $170 | $140.92 | +20.64% | 3 | Mar 26, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Buy | €40.00 → €53.00 | €49.04 | +8.08% | 5 | Mar 11, 2026 | |
| BME: GRF Grifols, S.A. | Downgraded: Hold | €12.00 → €11.00 | €9.71 | +13.31% | 7 | Mar 10, 2026 | |
| ALVO Alvotech | Reiterated: Buy | $14 → $10 | $5.34 | +87.27% | 4 | Dec 3, 2025 | |
| SWX: LONN Lonza Group AG | Reiterated: Buy | CHF 650.00 | CHF 545.00 | +19.27% | 10 | Dec 3, 2025 | |
| SWX: SDZ Sandoz Group AG | Reiterated: Hold | CHF 38.00 → CHF 50.00 | CHF 67.88 | -26.34% | 4 | Dec 3, 2025 | |
| ETR: MRK Merck KGaA | Reiterated: Hold | €130.00 → €135.00 | €131.45 | +2.70% | 5 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $36 | $35.69 | +0.87% | 11 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €300.00 | €248.30 | n/a | 3 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €250.00 | €196.10 | n/a | 3 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | 2,100p → 2,400p | 1,596p | n/a | 15 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | €12.00 | €2.88 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $14 | $1.67 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 912p | 1,305p | n/a | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €120.00 | €155.80 | n/a | 18 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $37 → $39 | $82.19 | n/a | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | CHF 4.00 → CHF 1.00 | CHF 4.90 | n/a | 11 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $16 | $7.40 | n/a | 4 | Dec 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €11.50 → €11.00 | €10.60 | n/a | 5 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 | $39.19 | n/a | 2 | Oct 4, 2023 |
Novo Nordisk
Sep 11, 2026
Downgraded: Sell
Price Target: $40
Current: $43.19
Upside: -7.39%
Novartis AG
Sep 1, 2026
Reiterated: Buy
Price Target: CHF 135.00
Current: CHF 116.02
Upside: +16.36%
Galderma Group AG
Apr 27, 2026
Reiterated: Hold
Price Target: CHF 155.00 → CHF 160.00
Current: CHF 157.85
Upside: +1.36%
Novartis AG
Mar 26, 2026
Reiterated: Buy
Price Target: $143 → $170
Current: $140.92
Upside: +20.64%
Bayer Aktiengesellschaft
Mar 11, 2026
Reiterated: Buy
Price Target: €40.00 → €53.00
Current: €49.04
Upside: +8.08%
Grifols, S.A.
Mar 10, 2026
Downgraded: Hold
Price Target: €12.00 → €11.00
Current: €9.71
Upside: +13.31%
Alvotech
Dec 3, 2025
Reiterated: Buy
Price Target: $14 → $10
Current: $5.34
Upside: +87.27%
Lonza Group AG
Dec 3, 2025
Reiterated: Buy
Price Target: CHF 650.00
Current: CHF 545.00
Upside: +19.27%
Sandoz Group AG
Dec 3, 2025
Reiterated: Hold
Price Target: CHF 38.00 → CHF 50.00
Current: CHF 67.88
Upside: -26.34%
Merck KGaA
Dec 3, 2025
Reiterated: Hold
Price Target: €130.00 → €135.00
Current: €131.45
Upside: +2.70%
Dec 3, 2025
Reiterated: Buy
Price Target: $28 → $36
Current: $35.69
Upside: +0.87%
Apr 22, 2025
Reiterated: Buy
Price Target: €300.00
Current: €248.30
Upside: n/a
Apr 22, 2025
Reiterated: Buy
Price Target: €250.00
Current: €196.10
Upside: n/a
Feb 12, 2025
Reiterated: Hold
Price Target: 2,100p → 2,400p
Current: 1,596p
Upside: n/a
Jul 29, 2024
Downgraded: Hold
Price Target: €12.00
Current: €2.88
Upside: n/a
Jul 29, 2024
Downgraded: Hold
Price Target: $14
Current: $1.67
Upside: n/a
Jul 15, 2024
Reiterated: Buy
Price Target: 912p
Current: 1,305p
Upside: n/a
May 15, 2024
Reiterated: Hold
Price Target: €120.00
Current: €155.80
Upside: n/a
May 8, 2024
Reiterated: Hold
Price Target: $37 → $39
Current: $82.19
Upside: n/a
Apr 3, 2024
Reiterated: Sell
Price Target: CHF 4.00 → CHF 1.00
Current: CHF 4.90
Upside: n/a
Dec 29, 2023
Reiterated: Hold
Price Target: $16
Current: $7.40
Upside: n/a
Nov 13, 2023
Reiterated: Hold
Price Target: €11.50 → €11.00
Current: €10.60
Upside: n/a
Oct 4, 2023
Reiterated: Hold
Price Target: $10
Current: $39.19
Upside: n/a